Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Am J Transplant. 2015 Jul;15(7):1817–1826. doi: 10.1111/ajt.13320

Figure 2. ICER (€ per QALY gained) values changing the SOF/RBV treatment duration strategies in the HCV-CIRRH (A) and HCV-HCC scenario (B).

Figure 2

HCV, hepatitis C virus; HCV-CIRRH, HCV cirrhotic patient listed for liver transplantation; HCV-HCC, HCV patient with hepatocellular carcinoma listed for liver transplantation; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SOF/RBV, sofosbuvir in combination with ribavirin treatment; WTP, willingness to pay.